07.00 Registration open
07.30 – 08.20 Breakfast teaching course – Muscle & Nerve
Room: Auditorium

  1. Congenital myopathies
    Francesco Muntoni, United Kingdom
  2. Inflammatory (radiculo)neuropathies
    Nortina Shahrizaila, Malaysia
08.30 – 09.15 Plenary lecture – Expected developments in the next 2 years
Room: Auditorium

  1. Expected developments in the next two years
    Ingrid Tein, Canada
09.15 – 10.00 Plenary lecture – Ethics in pediatric neurology
Room: Auditorium

  1. Ethics in pediatric neurology
    Bernard Dan, Belgium
10:00 – 10.30 BREAK
10.30 – 12.00 Parallel expert session 1 – Neuromuscular disorders – treatment
Room: E104-E107
Chair: Francesco Muntoni, United Kingdom
Co-chair: Lilian Sie, the Netherlands

  1. Treatment of Pompe’s disease where are we now?
    Ans van der Ploeg, the Netherlands
  2. Diagnosis and treatment of muscle channelopathies
    Francesco Muntoni, United Kingdom
  3. Update on treatment of Duchenne muscular dystrophy
    Erik Niks, the Netherlands

Parallel expert session 2 – Movement disorders – treatment
Room: Auditorium

Chair: Jean-Pierre Lin, United Kingdom
Co-chair: Michèl Willemsen, the Netherlands

  1. Deep Brain Stimulation
    Jean-Pierre Lin, United Kingdom
  2. Phenotypes, genotypes and treatment of paroxysmal movement disorders
    Laura Silveira-Moriyama, Brazil
  3. Clinical presentations, animal models and potential treatment of AADC
    Wang-Tso Lee, Taiwan, ROC

Parallel expert session 3 – Oncology
Room: Emerald Room

Chair: David Walker, United Kindom
Co-chair: Annemarie Fock, the Netherlands

  1. Novel strategies for the treatment of pontine glioma?
    Dannis van Vuurden, the Netherlands
  2. Strategies to minimise brain injury associated childhood brain tumour
    David Walker, United Kingdom
  3. Late effects of cancer treatment
    Brice Fresneau, France

Parallel expert session 4 – Cerebral Palsy
Across the world
Room: Forum

Chair: Jeroen Vermeulen, the Netherlands
Co-chair: Stephen Back, U.S.A.

  1. CP across the world care for handicapped children in resource rich countries
    Jeroen Vermeulen, the Netherlands
  2. CP across the world bilirubin encephalopathy
    Arushi Saini, India
  3. CP across the world care for handicapped children in Brazil
    Lucia Braga, Brazil
12.00 – 14.00 LUNCH
12.15 – 13.45 ICNC focus lunch symposium 1 – Cerebral Palsy – Practical Guide for Diagnosis, Evaluation and Treatment
Room: Auditorium
Chair: Hilla Ben-Pazi, Israel

  1. Genetic Diagnosis in Cerebral Palsy – Go for the cause
    Hilla Ben- Pazi, Israel
  2. Evaluation of children with CP- Scales and Outcomes
    Hortensia Gimeno, United Kingdom
  3. Neurophysiology and Neuropharmacolgy: what’s new on the horizon?
    Jonathan Mink, U.S.A.

ICNC focus lunch symposium 2 – Pyridoxine-Dependent Epilepsy: 2016 update on phenotype, diagnosis, treatment
Room: E104-E107

Chair: Clara van Karnebeek, Canada
Co-chair: Hans Hartmann, Germany

  1. Evolving phenotype & neurodevelopmental outcomes
    Sidney Gospe, U.S.A.
  2. Overview of biochemistry and genetics
    Emma Footitt, United Kingdom
  3. Triple therapy to improve seizure control & neurodevelopment
    Clara van Karnebeek, Canada

ICNC focus lunch symposium 3 – Recent advances on striatal necrosis in childhood
Room: Emerald Room

Chair: Kling Chong, UK
Co-Chair: Russel Dale, Australia

  1. Immune mediated basal ganglia injury
    Shekeeb Mohammed, Australia
  2. Interferonopathies
    John Livingston, United Kingdom
  3. Treatable causes of Leigh syndrome
    Belen Perez Duenas, Spain

Sponsored lunch symposium 4
(no part of the CME accreditation)
Room: Forum

14.00 – 16.00 Parallel platform sessions 1 – Cerebral Palsy
Room: Auditorium
Chair: Anna Jansen, Belgium
Co-chair: Arushi Gahlot Saini, India

  1. Presentation a pilot study of the effects of selective Dorsal Rhizotomy in children with Severe Spastic Cerebral Palsy, GMFCS IV, at one year post-operatively
    Lucinda Carr, United Kingdom
  2. Clinical profile of children with Cerebral Palsy born term compared to late- and post-term
    Russell Frank, Canada
  3. Prediction of outcome using a new preterm white matter injury classification
    Miriam Martinez-Biarge, United Kingdom
  4. Cerebral palsy (CP) in the Swedish national cohort of extremely preterm infants (EXPRESS); spectrum and co-morbidities
    Maria Hafström, Norway
  5. Clinical and magnetic resonance imaging characteristics in children with Dyskinetic Cerebral Palsy due to Neonatal Hyperbilirubinemia- A developing country experience
    Arushi Gahlot Saini, India
  6. Complementary and Alternative medicine use among children with chronic neurological disorders in Enugu, Nigeria
    Ngozi Ojinnaka, Nigeria
  7. Mechanisms of transcranial direct-current stimulation (tDCS)-enhanced motor learning in healthy children
    Patrick Ciechanski, Canada

Parallel platform sessions 2 – Epilepsy – treatment and outcome 2
Room: Forum

Chair: Harry Chugani, U.S.A.
Co-chair: Hilde Braakman, the Netherlands

  1. Evaluation of efficacy, safety and workload of inpatient and outpatient initiation of the Ketogenic Diet in children (0-18 y) with refractory epilepsy
    Elles van der Louw, the Netherlands
  2. Efficacy and safety of Lacosamide in children
    Dipak Ram, United Kingdom
  3. Addition of Pyridoxine to prednisolone in the treatment of infantile spasms: A randomized controlled trial
    Suvasini Sharma, India
  4. Low-dose Add-on Fenfluramine in Dravet Syndrome: Effect on seizure control, sleep quality, and quality of Life in a prospective open-label study
    An-Sofie Schoonjans, Belgium
  5. Efficacy of cannabidiol in refractory epilepsy in children and adolescents – prospective open label F/U registry of 45 patients
    Shay Menascu, Israel

Parallel platform sessions 3 – Movement disorders
Room: E104-E107

Chair: Wang-Tso Lee, Taiwan, ROC
Co-chair : Jolanda Schieving, the Netherlands

  1. Diagnostic approach for pediatric patients with Dystonia
    Alfredo Cerisola, Uruguay
  2. Psychiatric comorbidities in children with Dystonia
    Michelle Lorentzos, Australia
  3. DNAJC6 mutations in childhood onset Parkinsonism-Dystonia
    Elisenda Cortes-Saladelafont, Spain
  4. Segawa disease; clinical heterogeneity
    Yoshiko Nomura, Japan
  5. The clinical spectrum of stereotypic movement disorders (SMD) in typically developing children and adolescents – a video and record review
    Michael Rotstein, Israel
  6. GNAO1 – expanding a new phenotype – severe hyperkinetic movement disorder with episodic-life threatening exacerbations responsive to deep brain stimulation
    Michaela Waak, Australia
  7. Delineation of the movement disorder spectrum in FOXG1-Related Disease
    Papandreou Apostolos, United Kingdom

Parallel platform sessions 4 – Neuromuscular disorders – treatment
Room: Emerald Room

Chair: Carsten Bonnemann, U.S.A.
Co-Chair: Jikke-Mien Niermeijer, the Netherlands

  1. Ataluren confirmatory trial in DMD: Effect of Ataluren on activities of daily living in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
    Rosalie Quinlivan, United Kingdom
  2. Results of North Star Ambulatory Assessments in the phase 3 ataluren confirmatory trial in patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)
    Francesco Muntoni, United Kingdom
  3. Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical update and longitudinal comparison to external controls on six-minute walk test (6MWT)
    Emily Naughton, U.S.A.
  4. Development of a Prognostic Model for 1-year Change in 6-Minute Walk Distance (6MWD) in Patients with Duchenne Muscular Dystrophy (DMD)
    Nathalie Goemans, Belgium
  5. Retrospective review of cause of death in Duchenne muscular dystrophy in the North East of England in the last 10 years
    Henriette van Ruiten, United Kingdom
  6. Juvenile Myasthenia Gravis: Experience from a tertiary care centre
    Meenal Garg, India
  7. Asymptomatic or oligosymptomatic hyperckemia in pediatric patients
    Eliana Cavassa, Argentina
 16.00 – 16.30 BREAK
 16.30 – 17.20 Poster Viewing

Tour 1: Epilepsy 1
Tour 2: Epilepsy 2
Tour 3: Epilepsy 3
Tour 4: Epilepsy 4
Tour 5: Syndromes & Autism 1
Tour 6: Syndromes & Autism 2
Tour 7: Immune-mediated disorders
Tour 8: Miscellaneous 1
Tour 9: Miscellaneous 2
Tour 10: Neurometabolic disorders 1
Tour 11: Neurometabolic disorders 2
Tour 12:  Neuromuscular disorder
Tour 13: Stroke and vascular disorders
Tour 14: Cerebral Palsy 1
Tour 15: Cerebral Palsy 2
Tour 16: Movement disorders

17.30 – 18.00 Closing Ceremony
Presentation ICNC 2018
Award winners announcement
Room: Auditorium